Ajayi G O
Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.
Clin Exp Obstet Gynecol. 2011;38(2):162-4.
At present, the most effective trisomy 21-screening method is the estimate of risk combining maternal age, fetal nuchal translucency, beta-hCG and pregnancy-associated PAPP-A.
The aim of this study was to investigate the possible effect of fetal gender in first trimester Down's syndrome screening markers.
Retrospective study.
Prenatal Diagnosis Centre in a tertiary hospital in Lagos.
Of a total of 350 pregnancies in which fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A were performed were included in this study. These markers were investigated to see if they differed on the basis of fetal gender.
PAPP-A levels were higher in female fetuses although the difference was not statistically significant. Nuchal translucency was 0.099 mm more in male fetuses.
The results suggest that first trimester markers differ on gender but are of no clinical significance, confirming the result of other authors.
目前，最有效的21三体综合征筛查方法是结合孕妇年龄、胎儿颈部透明带厚度、β-人绒毛膜促性腺激素（β-hCG）和妊娠相关血浆蛋白A（PAPP-A）来评估风险。
本研究旨在探讨胎儿性别对孕早期唐氏综合征筛查标志物的可能影响。
回顾性研究。
拉各斯一家三级医院的产前诊断中心。
本研究纳入了总共350例进行了胎儿颈部透明带厚度及孕妇血清游离β-hCG和PAPP-A检测的妊娠病例。对这些标志物进行研究，以观察它们是否因胎儿性别而异。
女性胎儿的PAPP-A水平较高，尽管差异无统计学意义。男性胎儿的颈部透明带厚度多0.099毫米。
结果表明，孕早期标志物存在性别差异，但无临床意义，这与其他作者的结果一致。
